SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

Key Points

• Unusually large options activity: Traders bought 15,545 call options on SLS on Tuesday, a 56% increase versus the stock's average daily call volume of 9,947.
• Shares traded up to $1.60 on roughly 2.9 million shares, and the company beat quarterly expectations with EPS of ($0.06) versus consensus ($0.08), though analysts still forecast a full-year loss (around -$0.57).
• Notable institutional moves include Anson Funds increasing its stake by 535.7% to 7.58 million shares, while analyst sentiment is mixed—an average "Hold" rating with a $7 target and a separate Weiss Ratings "sell (d-)" opinion.

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 15,545 call options on the company. This represents an increase of 56% compared to the average daily volume of 9,947 call options.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock traded up $0.19 during trading on Tuesday, reaching $1.60. The company had a trading volume of 2,895,469 shares, compared to its average volume of 2,800,879. The firm's 50 day simple moving average is $1.78 and its two-hundred day simple moving average is $1.77. SELLAS Life Sciences Group has a one year low of $0.77 and a one year high of $2.48. The company has a market capitalization of $199.50 million, a PE ratio of -4.98 and a beta of 2.64.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last announced its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. Analysts forecast that SELLAS Life Sciences Group will post -0.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $7.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several hedge funds and other institutional investors have recently made changes to their positions in SLS. Anson Funds Management LP grew its holdings in SELLAS Life Sciences Group by 535.7% in the 1st quarter. Anson Funds Management LP now owns 7,579,095 shares of the company's stock valued at $8,185,000 after buying an additional 6,386,829 shares during the last quarter. Virtu Financial LLC grew its stake in shares of SELLAS Life Sciences Group by 30.9% in the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock worth $58,000 after acquiring an additional 12,706 shares during the last quarter. Blair William & Co. IL bought a new position in SELLAS Life Sciences Group during the second quarter worth $35,000. Equitable Holdings Inc. raised its stake in SELLAS Life Sciences Group by 58.6% during the 3rd quarter. Equitable Holdings Inc. now owns 27,060 shares of the company's stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock valued at $32,000 after purchasing an additional 9,299 shares during the period. 17.38% of the stock is owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.